Controlling the Cost of Drugs: the Canadian Experience
نویسندگان
چکیده
In 1969 Canada began programs at both the national and provincial levels to lower prescription drug prices. These programs may have contributed to a significant decline between 1970 and 1974 of 39 percent in the average price of 16 drugs selected for study. During this time, the average price for the same drugs in the United States declined only 1.4 percent. One major program, a change in the compulsory patent licensing, is described and analyzed. Other Canadian programs, designed to promote competition in the drug industry, and their efforts are discussed.
منابع مشابه
Cost-Sharing Rates Increase During Deep Recession: Preliminary Data From Greece
Background Measures taken over the past four years in Greece to reduce pharmaceutical expenditure have led to significant price reductions for medicines, but have also changed patient cost-sharing rates for prescription drugs. This study attempts to capture the resulting increase in patients’ out-of-pocket (OOP) expenses for prescription drugs during the 2011-2014 period. Methods The authors ...
متن کاملCosts of treatment after renal transplantation: is it worth to pay more?
Objectives: The present study aimed to provide an estimation of the current financial burden of renal transplantation therapy for insurance organisations.Methods: An Excel-based model was developed to determine the treatment costs of current clinical practice in renal transplantation therapy (RTT). Inputs were derived from Ministry of Health and insurance organizations` database, hospital and p...
متن کاملCosts of treatment after renal transplantation: is it worth to pay more?
Objectives: The present study aimed to provide an estimation of the current financial burden of renal transplantation therapy for insurance organisations.Methods: An Excel-based model was developed to determine the treatment costs of current clinical practice in renal transplantation therapy (RTT). Inputs were derived from Ministry of Health and insurance organizations` database, hospital and p...
متن کاملAttitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs
Background Although medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the attitude of Iranian medical oncologists toward some e...
متن کاملIt Won’t Be Easy: How to Make Universal Pharmacare Work in Canada
One of the glaring gaps in Canada’s universal healthcare system is the low level of public financing of prescription drugs - 42.7% of total spending in 2018. At the federal level there is renewed interest in moving towards universal coverage, supported by a recently commissioned report on how to achieve it. It will take superb political navigation to extract Canadian ph...
متن کامل